Effect of Helicobacter Pylori Treatment on Idiopathic Central Serous Chorioretinopathy (ICSCR)

This study has been completed.
Sponsor:
Information provided by:
Tabriz University
ClinicalTrials.gov Identifier:
NCT00817245
First received: January 1, 2009
Last updated: January 5, 2009
Last verified: January 2009

January 1, 2009
January 5, 2009
March 2008
October 2008   (final data collection date for primary outcome measure)
Subretinal fluid level [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00817245 on ClinicalTrials.gov Archive Site
time of sub macular fluid absorption [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Effect of Helicobacter Pylori Treatment on Idiopathic Central Serous Chorioretinopathy (ICSCR)
Effect of Helicobacter Pylori Treatment on Remission of Idiopathic Central Serous Chorioretinopathy (ICSCR)

Etiology of ICSCR is not known however recent studies regard the role of immunologic and infectious processes in the pathogenesis of ICSCR.one of these hypothesis is the role of helicobacter pylori in the pathogenesis of ICSCR so perhaps treatment of h pylori have positive effect on the remission of ICSCR.

we will choose 50 cases of patients with ICSCR who are infected with h.pylori.25 cases will receive anti h.pylori regiment and 25 cases as controls will receive no medication.then we will compare the time of submacular fluid resorption and macular thickness and visual acuity among these two groups.

Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Central Serous Chorioretinopathy
Drug: omeprazole, Amoxicillin, metronidazole
we will evaluate the effect of medication(anti h.pylori) on the remission of ICSCR
Other Name: treatment of Central serous chorioretinopathy
  • Active Comparator: 1
    Oral Amoxicillin Capsule Metronidazole Tablet Omeprazole Capsule
    Intervention: Drug: omeprazole, Amoxicillin, metronidazole
  • No Intervention: 2
    No medical treatment
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
January 2009
October 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • the persons who are infected with helicobacter pylori and have ICSCR

Exclusion Criteria:

  • history of previous eye surgery ,to have indication of laser therapy,corticosteroid therapy,pregnancy,
Both
28 Years to 40 Years
No
Contact information is only displayed when the study is recruiting subjects
Iran, Islamic Republic of
 
NCT00817245
86-47
Yes
Alireza Javadzadeh, Tabriz University of Medical Sciences
Tabriz University
Not Provided
Study Chair: Alireza Javadzadeh Alireza Javadzadeh
Tabriz University
January 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP